KLK3 and pachyonychia congenita: Presentation of PC in the PSA era (when PSA testing has been available) has featured lower diagnostic age, less advanced tumor characteristics (lower tumor T stage, according to the clinical tumor‐node‐metastasis, TNM system) and lower proportion of patients presenting with distant metastases.2